611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA
Acquire Orphai Therapeutics, LLC
Reports Second Quarter 2026 Financial Results and Corporate Update
CEO and COO Conditional Resignations; Dirk Thye and Brendan Hannah
Amended material disclosure
Reverse Stock Split Approved at 1-for-20 Ratio by Quince Therapeutics
Election of Director - June Bray Approved by Stockholders
Other Events
Q1
FY 2025
Notice of Late Filing for Annual Report
Q3
Q2
FY 2024
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence